Camurus AB (NASDAQ STO: CAMX) has appointed Dr. Alberto M. Pedroncelli, MD, PhD, as the new Chief Medical Officer (CMO) and a member of the company’s executive management team effective from June 1, 2023. This announcement was made today, and it is a significant milestone for Camurus as the company seeks to expand its capabilities in the development of innovative treatments for rare diseases.
A Leading Global Expert in Clinical Development and Medical Affairs Dr. Pedroncelli is a leading global expert in clinical development and medical affairs within the field of endocrinology and oncology. He has held several senior leadership positions in the pharmaceutical industry, including head of clinical development & medical affairs, global endocrinology at Recordati, and different senior leadership positions at Novartis, where he was responsible for global clinical programs in rare diseases. He was also involved in the successful US and European regulatory submissions of osilodrostat (Isturisa®) for the treatment of Cushing’s syndrome.
A Strong Commitment to Patient Care
According to Fredrik Tiberg, President, and CEO of Camurus, “We are delighted to have Alberto joining Camurus as our new Chief Medical Officer ahead of Phase 3 results and planned regulatory submissions for CAM2029. Alberto’s strong commitment to patient care, leading position in the endocrine and neuroendocrine cancer communities, and track record from successful clinical development and market access processes for global pharmaceutical brands in rare disease areas makes him a great addition to our growing team at Camurus.” Impressed by the Company’s Development, Unique Technology Platform, and Promising Portfolio Dr. Pedroncelli said, “I have followed Camurus for many years and I am impressed by the company’s development, unique technology platform, and promising portfolio of drug candidates for the treatment of rare diseases, not least CAM2029. The product has several potential benefits for patients and the possibility of becoming a new standard treatment for acromegaly and neuroendocrine tumors. I look forward to working together with my talented colleagues at Camurus to increase the availability of effective treatments for patients with severe and often chronic medical conditions.” Peter Hjelmström, the previous Chief Medical Officer, has left Camurus after eight productive years to pursue other engagements. The appointment of Dr. Pedroncelli marks a significant step forward for Camurus in its commitment to developing innovative treatments for rare diseases and its focus on patient care.Conclusion
Camurus’ appointment of Dr. Alberto M. Pedroncelli, MD, PhD, as its new Chief Medical Officer is a significant development in the pharmaceutical industry. Dr. Pedroncelli’s track record in clinical development and medical affairs, coupled with his strong commitment to patient care, makes him a great addition to Camurus’ growing team. His appointment comes at a crucial time as the company seeks to expand its capabilities in the development of innovative treatments for rare diseases.
